Volume 29, Issue 179 (12-2019)                   J Mazandaran Univ Med Sci 2019, 29(179): 93-103 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ramezani A, Rezvan N, Nazari M. Changes in Serum Levels of FABP4 and HsCRP after Administration of Omega-3 Fatty Acids Separately or + Vitamin E in Patients with Coronary Artery Disease. J Mazandaran Univ Med Sci. 2019; 29 (179) :93-103
URL: http://jmums.mazums.ac.ir/article-1-13154-en.html
Abstract:   (838 Views)

 Background and purpose: Inflammatory markers of A-FABP and HsCRP play an important role in progression of cardiovascular disease. Anti-inflammatory and anti-platelet aggregation effects of omega-3 fatty acids are known. The aim of this study was to investigate the effects of omega-3 and omega-3+ vitamin E supplements on serum levels of these inflammatory markers.
Materials and methods: This double-blind parallel trial was performed in 62 patients with coronary artery disease in Tehran Heart Center. Patients were divided into three groups to receive omega-3 fatty acids, omega-3+ vitamin E supplements, and placebo (oral paraffin) for 8 weeks. At the beginning of the study and end of week eight the serum levels of A-FABP and HsCRP were measured and the ratio of adiponectin to A-FAPP was calculated. Nutrition data were analyzed using Nutritionist IV and data analysis was done using SPSS V18.
Results: At the end of the trial, serum level of FABP4 decreased significantly in the groups that received Omega-3 fatty acids+ vitamin E and Omega-3 fatty acids (P= 0.02 and P= 0.04, respectively) and its value was similar between the three groups (P= 0.34). The ratio of adiponectin to FABP4 (P= 0.009) and serum HsCRP (P = 0.002) were found to be different between the three groups.
Conclusion: According to this study, using omega-3 fatty acids+ vitamin E reduces the level of HsCRP and increases the ratio of adiponectin to FABP4 without any effect on the levels of FABP4. Consequently, this regimen will reduce inflammatory parameters and improve the complications of coronary artery disease.
(Clinical Trials Registry Number: IRCT2013080514273N1)

Full-Text [PDF 315 kb]   (232 Downloads)    
Type of Study: Research(Original) | Subject: Nutrition

Add your comments about this article : Your username or Email:

Send email to the article author

© 2020 All Rights Reserved | Journal of Mazandaran University of Medical Sciences

Designed & Developed by : Yektaweb